
About the Sumit
The decisions made in the next few years will define the trajectory of human health for decades to come. SOPHiA GENETICS brings together the pioneers making those decisions — clinicians, researchers, and biopharma leaders who refuse to accept the status quo.
Join us September 22–23, 2026 in Nashville for two immersive days at the intersection of AI, multimodal data, and precision medicine. Where bold ideas meet the real-world science to make them possible.
ATTENDEE VOICES
“Huge thanks to SOPHiA GENETICS for organizing this impactful event and for the opportunity to network with so many passionate leaders driving innovation in AI and life science.” – 2025 SUMMIT ATTENDEE
Save the date. Register your interest. Be part of what’s next.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.